EN 简
About CARsgen®
We focus on innovative CAR T-cell therapies

We are biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases.

Read More
About CARsgen<sup>®</sup>
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR
<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor
News Center
2025-10-13
CARsgen Announces Premarket Approval Application of Claudin18.2 Companion Diagnostic Kit Accepted by China’s NMPA
2025-10-08
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
2025-10-06
ASH Preview | CARsgen to Present Results on Allogeneic BCMA CAR-T CT0596 at ASH 2025 Annual Congress
2025-09-24
Passing Away of Non-Executive Director
2025-09-18
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
2025-09-12
Preliminary Clinical Data of Allogeneic CD19/CD20 CAR-T Product for Mantle Cell Lymphoma Reported at Academic Conference